Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Vα14 natural killer T cells

Immunology Letters

Volumn 106, Issue 1, 2006, Pages 82-90

  Kuwatani, Masaki ^a,b   Ikarashi, Yoshinori ^a   Iizuka, Akira ^a,c   Kawakami, Chihiro ^a   Quinn, Gary ^a   Heike, Yuji ^a   Yoshida, Mitsuzi ^a   Asaka, Masahiro ^b   Takaue, Yoichi ^c   Wakasugi, Hiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Galactosylceramide; Chimerism; Graft versus host disease; NKT cell

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON ANTIBODY; INTERLEUKIN 4 ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL TRANSFER; CHIMERA; FEMALE; IN VITRO STUDY; LIVER INJURY; MORBIDITY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL;

ACUTE DISEASE; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL SEPARATION; CELLS, CULTURED; CHIMERISM; FEMALE; GALACTOSYLCERAMIDES; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 33746242385     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2006.05.001     Document Type: Article

References (38)

1. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
2. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in non-obese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 187 (1998) 1047-1056
3. Moodycliffe A.M., Nghiem D., Clydesdale G., and Ullrich S.E. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 1 (2000) 521-525
4. + NKT cells against melanoma. Br J Cancer 85 (2001) 741-746
5. + T cells reciprocally regulate acute graft-versus-host disease. J Exp Med 189 (1999) 1073-1081
6. Burnett A.K., Hann I.M., Robertson A.G., Alcorn M., Gibson B., McVicar I., et al. Prevention of graft-versus-host disease by in vitro T cell depletion: reduction in graft failure with augmented total body irradiation. Leukemia 2 (1988) 300-303
7. Deeg H.J. Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients. Bone Marrow Transplant 14 Suppl 4 (1994) S56-S60
8. Via C.S., Sharrow S.O., and Shearer G.M. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-versus-host disease. J Immunol 139 (1987) 1840-1849
9. + T cells. J Immunol 155 (1995) 2396-2406
10. Allen R.D., Staley T.A., and Sidman C.L. Differential cytokine expression in acute and chronic murine graft-versus-host-disease. Eur J Immunol 23 (1993) 333-337
11. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9 (2003) 1144-1150
12. + natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood 97 (2001) 2923-2931
13. Morecki S., Panigrahi S., Pizov G., Yacovlev E., Gelfand Y., Eizik O., et al. Effect of KRN7000 on induced graft-vs-host disease. Exp Hematol 32 (2004) 630-637
14. Hashimoto D., Asakura S., Miyake S., Yamamura T., Van Kaer L., Liu C., et al. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol 174 (2005) 551-556
15. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., and Baxter A.G. NKT cells: facts, functions and fallacies. Immunol Today 21 (2000) 573-583
16. + NKT cells after hematopoietic stem cell transplantation. Bone Marrow Transplant 34 (2004) 595-602
17. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8 (2002) 3702-3709
18. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103 (2004) 383-389
19. Lin H., Nieda M., and Nicol A.J. Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines. Eur J Immunol 34 (2004) 2664-2671
20. Brossay L., Chioda M., Burdin N., Koezuka Y., Casorati G., Dellabona P., et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 188 (1998) 1521-1528
21. + T cells in vitro. Hum Immunol 61 (2000) 357-365
22. van der Vliet H.J., Nishi N., Koezuka Y., von Blomberg B.M., van den Eertwegh A.J., Porcelli S.A., et al. Potent expansion of human natural killer T cells using α-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Meth 247 (2001) 61-72
23. Kronenberg M., and Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2 (2002) 557-568
24. - invariant Vα14 natural killer T (Vα14i NKT) cells using α-galactosylceramide and IL-2. Immunol Lett 101 (2005) 160-167
25. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.R., et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 192 (2000) 741-754
26. Yoshino S., Murata Y., and Ohsawa M. Successful induction of adjuvant arthritis in mice by treatment with a monoclonal antibody against IL-4. J Immunol 161 (1998) 6904-6908
27. Puliaev R., Nguyen P., Finkelman F.D., and Via C.S. Differential requirement for IFN-γ in CTL maturation in acute murine graft-versus-host disease. J Immunol 173 (2004) 910-919
28. Carnaud C., Lee D., Donnars O., Park S.H., Beavis A., Koezuka Y., et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163 (1999) 4647-4650
29. Xun C.Q., Tsuchida M., and Thompson J.S. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. Transplantation 64 (1997) 297-302
30. + T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. J Immunol 167 (2001) 2087-2096
31. Haraguchi K., Takahashi T., Matsumoto A., Asai T., Kanda Y., Kurokawa M., et al. Host-residual invariant NK T cells attenuate graft-versus-host immunity. J Immunol 175 (2005) 1320-1328
32. Fujii S., Shimizu K., Kronenberg M., and Steinman R.M. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs. Nat Immunol 3 (2002) 867-874
33. Ritchie D.S., Morton J., Szer J., Robert A.W., Durrant S., Shuttleworth P., et al. Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 9 (2003) 435-442
34. Childs R., Clave E., Contentin N., Jayasekera D., Hensel N., Leitman S., et al. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94 (1999) 3234-3241
35. Pan Y., Luo B., Sozen H., Kalscheuer H., Blazar B.R., Sutherland D.E., et al. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under non-myeloablative and irradiation-free conditioning therapy. Transplantation 76 (2003) 216-224
36. Atkinson K., Matias C., Guiffre A., Seymour R., Cooley M., Biggs J., et al. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 77 (1991) 1376-1382
37. Motohashi S., Kobayashi S., Ito T., Magara K.K., Mikuni O., Kamada N., et al. Preserved IFN-α production of circulating Vα24 NKT cells in primary lung cancer patients. Int J Cancer 102 (2002) 159-165
38. + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 116 (2005) 87-93